Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events

Clinical Cardiology
Anthony A BavryREACH Registry Investigators

Abstract

The benefit of aspirin among patients with stable atherosclerosis without a prior ischemic event is not well defined. Aspirin would be of benefit in outpatients with atherosclerosis with prior ischemic events, but not in those without ischemic events. Subjects from the Reduction of Atherothrombosis for Continued Health registry were divided according to prior ischemic event (n =21 724) vs stable atherosclerosis, but no prior ischemic event (n = 11 872). Analyses were propensity score matched. Aspirin use was updated at each clinic visit and considered as a time-varying covariate. The primary outcome was the first occurrence of cardiovascular death, myocardial infarction, or stroke. In the group with a prior ischemic event, aspirin use was associated with a marginally lower risk of the primary outcome at a median of 41 months (hazard ratio [HR]: 0.81, 95% confidence interval [CI]: 0.65-1.01, P = 0.06). In the group without a prior ischemic event, aspirin use was not associated with a lower risk of the primary outcome at a median of 36 months (HR: 1.03, 95% CI: 0.73-1.45, P = 0.86). In this observational analysis of outpatients with stable atherosclerosis, aspirin was marginally beneficial among patients with a prior ischemic eve...Continue Reading

References

May 15, 1991·Annals of Internal Medicine·P M RidkerC H Hennekens
Feb 15, 1980·JAMA : the Journal of the American Medical Association
Sep 14, 1999·Journal of the American College of Cardiology·M S LauerE J Topol
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Jan 12, 2008·The American Journal of Medicine·Jeffrey S BergerRichard C Becker
Sep 2, 2010·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Oct 4, 2012·JAMA : the Journal of the American Medical Association·Sripal BangaloreUNKNOWN REACH Registry Investigators
May 3, 2013·Cleveland Clinic Journal of Medicine·Ki Park, Anthony A Bavry
Sep 2, 2014·Recent Patents on Cardiovascular Drug Discovery·Islam Y ElgendyCharles R Conti
Apr 3, 2016·BMC Medical Research Methodology·David HajageYann De Rycke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.